Meeting
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
Presenter
Michael Dickinson, MBBS
The Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03467373
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7549)
DOI
10.1200/JCO.2023.41.16_suppl.7549
Abstract #
7549
Poster Bd #
100
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.
Speaker: Michael Dickinson, MBBS
Videos & Slides
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Speaker: Mark Hertzberg
Videos & Slides
2016 Gastrointestinal Cancers Symposium
Chair
Speaker: Daniel V.T. Catenacci, MD
Videos & Slides
2024 ASCO Annual Meeting
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).
Speaker: Jurriaan Brouwer, PhD